← back to search

W. Timothy Garvey

University of Alabama at Birmingham · US
Area of research
Physiology · Molecular Biology
Research interest
Research interests include Adipose Tissue and Metabolism, Metabolism, Diabetes, and Cancer, Adipokines, Inflammation, and Metabolic Diseases, and Pancreatic function and diabetes.
h-index
44
citations
9,223
works
130
NIH funding
primary concept
Medicine
email

Recent publications

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
New England Journal of Medicine 2025cited by 74position: middledoi
American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update
Endocrine Practice 2025cited by 53position: middledoi
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial
The Lancet Diabetes & Endocrinology 2025cited by 17position: middledoi
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year <scp>SURMOUNT</scp> ‐1 trial
Diabetes Obesity and Metabolism 2025cited by 8position: lastdoi
Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study
Diabetologia 2025cited by 7position: middledoi
Adiposity-Based Chronic Disease
Lifestyle Medicine 2025cited by 1position: firstdoi
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Metabolism 2024cited by 76position: middledoi
Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective Cohorts
JACC Advances 2024cited by 19position: lastdoi
Effective but inaccessible antiobesity medications: A call for sharing responsibility for improving access to evidence-based care
Cleveland Clinic Journal of Medicine 2024cited by 3position: lastdoi
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet 2023cited by 360position: lastdoi
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Diabetes Obesity and Metabolism 2023cited by 83position: lastdoi
Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network
Journal of the American Heart Association 2023cited by 19position: middledoi
Proinsulin–to–C-Peptide Ratio as a Marker of β-Cell Function in African American and European American Adults
Diabetes Care 2023cited by 13position: middledoi
Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program
Population Health Management 2023cited by 8position: firstdoi
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Endocrine Practice 2022cited by 931position: middledoi
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Endocrine Practice 2022cited by 459position: middledoi
Tribbles Homolog 3 Mediates the Development and Progression of Diabetic Retinopathy
Diabetes 2021cited by 21position: middledoi
Genetic landscape of Gullah African Americans
American Journal of Physical Anthropology 2021cited by 12position: middledoi
Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
Journal of the Endocrine Society 2021cited by 10position: middledoi
Insulin Resistance Moderates the Association Between BMI and Metabolic Syndrome Severity in Women 4–10 Years After Pregnancy, Independent of Gestational Diabetes Status
Journal of the Endocrine Society 2021cited by 0position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
Endocrine Practice 2020cited by 601position: middledoi
Canagliflozin extends life span in genetically heterogeneous male but not female mice
JCI Insight 2020cited by 118position: middledoi
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Journal of the American College of Cardiology 2020cited by 110position: lastdoi
Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study
PLoS Medicine 2020cited by 42position: lastdoi
Impact of a weight loss and fitness intervention on exercise‐associated plasma oxylipin patterns in obese, insulin‐resistant, sedentary women
Physiological Reports 2020cited by 28position: middledoi
In utero nutritional stress as a cause of obesity: Altered relationship between body fat, leptin levels and caloric intake in offspring into adulthood
Life Sciences 2020cited by 19position: lastdoi
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Diabetes Care 2019cited by 1,416position: middledoi
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary
Endocrine Practice 2019cited by 297position: middledoi
Exercise plasma metabolomics and xenometabolomics in obese, sedentary, insulin-resistant women: impact of a fitness and weight loss intervention
American Journal of Physiology-Endocrinology and Metabolism 2019cited by 39position: middledoi
Race affects the association of obesity measures with insulin sensitivity
American Journal of Clinical Nutrition 2019cited by 31position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alan J. Garber · Baylor College of Medicine9 papers (2013–2020)Jeffrey I. Mechanick · Mount Sinai Hospital9 papers (2014–2022)George Grunberger · Charles University8 papers (2013–2020)Yehuda Handelsman · Translational Research Institute for Metabolism and Diabetes8 papers (2013–2020)Daniel Einhorn · Corcept Therapeutics (United States)7 papers (2013–2020)Janet B. McGill · University of Colorado Denver6 papers (2014–2020)Guillermo E. Umpierrez · Emory University6 papers (2014–2020)Yuchang Fu · University of Alabama at Birmingham6 papers (2012–2018)Joshua I. Barzilay · Kaiser Permanente5 papers (2016–2020)Zachary T. Bloomgarden · Ruijin Hospital5 papers (2013–2019)Jeffrey R. Garber · Westmead Hospital5 papers (2016–2020)Ling Tian · Northwestern University5 papers (2012–2016)Irl B. Hirsch · University of Washington5 papers (2016–2020) · 5 papers (2016–2020)Samuel Dagogo‐Jack · University of Tennessee Health Science Center5 papers (2014–2019) · 5 papers (2016–2020)Paul S. Jellinger · Brigham and Women's Hospital5 papers (2016–2020) · 5 papers (2016–2020)Ralph A. DeFronzo · Georgetown University5 papers (2016–2020)Michael A. Bush · Nationwide Children's Hospital5 papers (2016–2020)